Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Akebia Therapeutics (AKBA)

Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Akebia Therapeutics: Q1 Earnings Snapshot AP - Thu May 7, 6:10AM CDT

Akebia Therapeutics: Q1 Earnings Snapshot

AKBA : 1.0200 (unch)
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights GlobeNewswire - Thu May 7, 6:00AM CDT

Q1 2026 Vafseo® (vadadustat) net product revenues grew to  $15.8 million ; Q1 2026 total net product revenues of $52.0 million Number of patients treated with Vafseo increased 60% in Q1 2026...

AKBA : 1.0200 (unch)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon May 4, 3:05PM CDT

CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

AKBA : 1.0200 (unch)
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology GlobeNewswire - Mon May 4, 7:00AM CDT

CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

AKBA : 1.0200 (unch)
Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights GlobeNewswire - Thu Apr 30, 3:05PM CDT

Akebia to Host Conference Call on May 7 at 8:00 a.m. EDT CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial...

AKBA : 1.0200 (unch)
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090 GlobeNewswire - Mon Apr 13, 7:00AM CDT

CAMBRIDGE, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.0200 (unch)
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium GlobeNewswire - Tue Apr 7, 7:00AM CDT

CAMBRIDGE, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.0200 (unch)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Thu Apr 2, 3:05PM CDT

CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

AKBA : 1.0200 (unch)
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors GlobeNewswire - Wed Apr 1, 3:05PM CDT

CAMBRIDGE, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.0200 (unch)
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 GlobeNewswire - Thu Mar 19, 3:05PM CDT

CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney...

AKBA : 1.0200 (unch)

Barchart Exclusives

Can November Soybeans Challenge Contract Highs? Strong Crush Demand and Seasonal Strength Say It's Possible Barchart - Sat May 23, 3:37PM CDT
November soybeans may be setting up one of the better seasonal opportunities in ag markets right now. Record crush demand, bullish technicals, and a weather market season are all lining up at the same time.MRCI research also shows Nov beans closed higher in this seasonal window 12 of the past 15 years, with 8 of those years seeing no daily closing drawdowns.That kind of historical consistency gets traders' attention! Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.